Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard® in At-Risk Patients without Symptomatic GERD
Portfolio Pulse from
Lucid Diagnostics Inc. has announced a $8 million NIH grant awarded to a consortium of academic medical centers to study the effectiveness of Lucid's EsoGuard® in detecting esophageal precancer in at-risk patients without symptomatic GERD.
February 27, 2025 | 1:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lucid Diagnostics has been awarded an $8 million NIH grant to study its EsoGuard® test for esophageal precancer detection in non-GERD patients, potentially expanding its market and application.
The NIH grant supports a study that could expand the use of Lucid's EsoGuard® test, potentially increasing its market reach and revenue. This positive development is likely to boost investor confidence and the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
PAVmed Inc., the parent company of Lucid Diagnostics, may benefit from the NIH grant awarded to Lucid for studying EsoGuard® in non-GERD patients, potentially enhancing its subsidiary's value.
As the parent company of Lucid Diagnostics, PAVmed stands to benefit from the potential market expansion and increased value of its subsidiary due to the NIH grant and study.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 70